Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Opsidio, LLC, a clinical stage biotechnology company dedicated to advancing innovative therapies for inflammatory diseases, today announced the dosing of the first patient in the Phase 2a clinical...
Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced that AbbVie (NYSE: ABBV), has...
Health Canada's approval of VENCLEXTA for newly diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from two Phase 3 trials - VIALE-A (M15-656) and VIALE-C...
SKYRIZI® is an interleukin-23 (IL-23) inhibitor used for the treatment of moderate to severe psoriasis.1 In clinical studies, SKYRIZI® significantly improved levels of skin clearance after just 16...
Psoriasis is a chronic condition affecting 125 million people worldwide and many patients despite treatment still do not reach their goals or lose treatment response over time. 1-3 SKYRIZI™ is a...
Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, and AbbVie (NYSE: ABBV), a research-based global ...
MONTREAL, Sept. 25, 2019 /CNW/ - AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, announced today that Alberta, Manitoba, British Columbia and Saskatchewan are...
INESSS recommends the reimbursement of VENCLEXTA® (venetoclax) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia (CLL).i Adult patients with CLL...
MAVIRET is the first and only 8-week, pan-genotypic treatment for patients with chronic hepatitis C virus (HCV) infection without cirrhosis and who are new to treatment.*1 MAVIRET is the only...
pERC conditionally recommends reimbursement of VENCLEXTA® (venetoclax) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at...
Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance (pCPA), Ontario is the first province to reimburse VENCLEXTA. VENCLEXTA is the first and only BCL-2...
Endometriosis affects up to one in 10 women of reproductive age in Canada.1 7 out of 10 women being managed for endometriosis have unresolved pain throughout the month.2 MONTREAL, May 21, 2019 /CNW/...
SKYRIZI™(risankizumab) is a novel, humanized immunoglobulin monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit to treat moderate to severe plaque psoriasis1 ....
MAVIRET is now listed under the "Régie de l'assurance maladie du Québec" List of Medications. MAVIRET is the first and only 8-week, pan-genotypic treatment for patients with chronic hepatitis C virus ...
Alberta, Saskatchewan and the Non-Insured Health Benefits (NIHB) Program list MAVIRET on their formularies MAVIRET is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C...
British Columbia PharmaCare lists MAVIRET on its formulary effective March 21, 2019 MAVIRET is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis...
Ontario will be the first province to reimburse MAVIRET as of February 28, 2019 MAVIRET is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and...
Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) and certain of its officers. The class action, filed in United States...
Updated label provides guidance that HUMIRA use can be considered while breastfeeding and should only be used during pregnancy if clearly needed1 Approval is supported by postmarketing data, a...
80% of patients with plaque psoriasis may develop nail psoriasis in their lifetime Over 50% of moderate to severe psoriasis patients suffer from nail disease Psoriasis patients with nail involvement...
If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis AbbVie's New Drug Submission is supported by data...
Approval Supported by Largest and Longest Head-to-Head Global Phase 3 Study Conducted in Multiple Sclerosis (MS) ZINBRYTA™ Significantly Reduced Multiple Measures of Disease Activity in Patients with ...
AbbVie, a global biopharmaceutical company, today announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for VENCLEXTA™ (venetoclax). The therapy has been approved for...
Hidradenitis suppurativa (HS) is a painful, chronic inflammatory skin disease MONTREAL, Jan. 6, 2016 /CNW/ - AbbVie, a global biopharmaceutical company, today announced that Health Canada approved...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.